Member Info for daveycaferacer

Another thing the Co. could do is to announce a Special Dividend of some decent amount, which they cam afford prior to a NASDAQ listing in Q1 next year

a poster on another BB raised a good point - Those who are short will need to pay the dividend to the lender and whilst forecast to be small, the Company could hike the dividend just to inflict pain on those willing to do harm to the Company and its long term Investors.
ex-divi date 14th Nov
payment date 5th Dec

More Tagrisso approvals in China
https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-approved-in-china-as-a-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-04092019.html

It is interesting that a number of Biotech's are still proceeding with their IPO's in HK, and activity appears to be increasing again. Now that Carrie Lam's extradition Bill is being shelved, hopefully this will boost confidence in the region and in HK's reputation as a great place to go public and raise capital.

https://www.straitstimes.com/business/companies-markets/hong-kong-ipo-activity-picking-up-after-quiet-aug

Immunotech Biopharm & Pharmaron are two that have applied for listings in the last couple of weeks alone

$20bn is certainly a stretch! I base that on p/s of 20, p/e of 50 and net margin of 20% - all a bit ambitious and assumes there is 100% pipeline success from here, which is probably a bit unrealistic. Bringing treatments from 3l to 2l and 1l will certainly help, and I have great hopes in particular for the syk inhibitor, maybe first in class and/or best in class.

Great points as ever jatw, and I agree the ADR's are what controls the price, and I've said for a number of years that the first U.S. launch will be a major boost.

You point about Long Investors buying whilst there is an overhang is a great one, although clearly that opportunity seems to be passing many of them by at the moment. I am buying because I think the price is very attractive.

I would be interested in others opinions on the current depressed share price and the fact we are 20% below the price when the secondary offering was announced. This is my current thoughts on the subject:-

1. HHHL/CKH secondary listing overhang
2. U.S. - China trade war
3. Hong Kong riots
4. Delay to HK IPO
5. Worldwide markets volatility
6. Possibly Institutional Investors waiting for any overhang to clear before investing further

Any pipeline progress is good and it's pleasing to see the Company always keeps to its commitments in terms of delivering updates. We also have the following to look forward to by the end of the year:

Savolitinib VKTORY PII data in Gastric
Surufatinib PIII data in non-P Net
Surufatinib NDA submission
Fruquinitinib PIII data in 3rd line NSCLC
Possible inclusion of Fruquintinib in the NRDL

I do not think the current valuation reflects where the Company is in its development, or its future prospects and most Analysts are of that opinion. I remain convinced this will be a $20bn Company in the next 10 years if the pipeline plays out as predicted.

I continue to buy.

Napo represents 0.35% of Burford’s litigation finance, so not the massive issue MW have falsely claimed

thanks for the biased advice utilitarian, how big is your short position?

Couldn't agree more with the concept of basing an investment strategy on evidence but what I am saying is it's unwise to read just the negative notes, there are positive ones and people would be advised to consider all opinions not just the long or short ones

Well done Steve Clayton at HL, you bought at the top and have sold at the bottom

Canaccord ramped and pumped Quindell to high heaven, so just to be clear, they do not always call things correctly and QPP was a classic example

More lies, blatant market manipulation and illegal activity designed to push down the share price

I am also blocked by TW, he simply blocks anyone who has a view which differs from his

He is a great protagonist of free speech, as long as it's only his speech

"major revelations" like their last damp squib? This is just a ploy to get weak holders to sell this morning

Grabbed a load at a bargain price

I meant Sharemuppets and Tom "the tw*t in the hat" Winnifrith

Another one of ************* pump and dumps

They could move off AIM and onto a Main Market listing if they wish to spend the extra money and comply with all the extra Main Market Listing governance, but even if they did, they will not be included in the FTSE100 Index as their mcap would be too small. I think they are right to pursue a U.S. listing and de-list from AIM.